XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
EXPENSES        
General and administrative $ 1,891,108 $ 1,145,152 $ 5,780,572 $ 3,186,575
Research and development 105,576 123,429 156,558 1,242,101
Credit loss expense - short-term note receivable (567,000) (99,000)
Total expenses 1,429,684 1,268,581 5,838,130 4,428,676
LOSS FROM OPERATIONS (1,429,684) (1,268,581) (5,838,130) (4,428,676)
OTHER EXPENSE (INCOME), NET        
Loss (Gain) on change in fair value of warrant liabilities 148,346 (1,231) 93,148 (361,137)
Loss on change in fair value of derivative liabilities 495,693 321,080
Loss on change in fair value of convertible debt 197,667 159,793
Interest expense 455,941 408,359 635,607 808,477
Interest income (193,819) (48,082) (449,249) (48,082)
Loss on issuance of convertible debt 91,943 358,279
Gain on voluntary conversion of convertible debt into common stock 27,790 (56,010)
Loss on monthly redemptions of convertible debt into common stock 208,852
Gain on settlements of accounts payable (348,305) (348,305)
Other income, net (6,547) (9,262)
Total other expense (income), net 608,135 527,677 531,242 873,892
LOSS BEFORE (BENEFIT FROM) PROVISION FOR INCOME TAXES (2,037,819) (1,796,258) (6,369,372) (5,302,568)
(BENEFIT FROM) PROVISION FOR INCOME TAXES (2,198) 35 800
NET LOSS FROM CONTINUING OPERATIONS (2,037,819) (1,794,060) (6,369,407) (5,303,368)
DISCONTINUED OPERATIONS        
Loss on disposal of discontinued operations, net of tax (100,000)
GAIN (LOSS) FROM DISCONTINUED OPERATIONS (100,000)
NET LOSS (2,037,819) (1,794,060) (6,369,407) (5,403,368)
Deemed dividend arising from preferred stock and warrant down-round provision (867,796) (27,587) (869,382) (87,604)
Net loss attributable to Qualigen Therapeutics, Inc $ (2,905,615) $ (1,821,647) $ (7,238,789) $ (5,490,972)
Total net loss per common share, basic $ (4.68) $ (4.70) $ (4.35) $ (24.93)
Total net loss per common share, diluted $ (4.68) $ (4.70) $ (4.35) $ (24.93)
Weighted-average number of shares outstanding, basic 620,694 387,878 1,662,223 220,221
Weighted-average number of shares outstanding, diluted 620,694 387,878 1,662,223 220,221